Harness the power of HRR
BRCA1/2 and beyondThe impairment in the DNA damage repair (DDR) genes is implicated in many cancers including breast, ovarian, prostate and pancreatic. Assessing the DDR status by expanding the biomarker profiling in the homologous recombination repair (HRR) pathway beyond BRCA1/2 is of significance for targeted therapy. Advances in NGS allow us to characterize biomarkers. However, operational bottlenecks such as resources, sample size, workflow optimization, data analysis and reporting still exist and can often hinder progress. Our QIAseq HRR Panel overcome such challenges and provide actionable biomarker insights with fewer resources.
Expand your HRR biomarker insights
Use our QIAseq HRR Panel to expand your biomarker coverage. The panel provides streamlined workflow, robust sensitivity with a low sample input across all 15 genes that were part of the PROfound study3.
Interested in a custom panel? We can customize panels with the genes of your interest or add it to the 15 genes we offer.
Key benefits of QIAseq HRR Panel
Maximize gene coverage, uniformity and precision
Maximize insights with fewer resources
The complete Sample to Insight workflow begins with DNA extraction, followed by library construction and target enrichment with QIAseq HRR Panels. Following NGS, data analysis is performed using the QIAGEN CLC Genomics Workbench. Detected variants can be interpreted with QIAGEN Clinical Insight (QCI) for QIAseq. Detect deficiencies in HRR by assessing variants in 15 HRR pathway genes including BRCA1 and BRCA2 using a streamlined workflow with fewer resources and less sample input.